therapy guidance

Leading change in

therapy guidance

Innovations in radiation treatment planning for prostate cancer

 

Today's challenging healthcare environment demands that you find new ways to drive clinical performance, enhance the patient experience and deliver economic value for your institution. We tackle these challenges with innovative tools and technologies, such as smart automation and MR-only simulation, to help you improve prostate cancer treatment planning and contribute to better outcomes for the patient.

arrow big
arrow 1
prostate-cancer-thumbnail

 

The challenge of prostate cancer treatment

Prostate cancer is the most common cancer in Europe for males, and the second most common worlwide. We're working to increase both the quality and efficiency of radiotherapy treatment planning for prostate cancer.

arrow 2
mr-only-thumbnail

 

Explore MR-only simulation*

Innovative MR-only simulation by Philips helps you rely on MR as a primary imaging modality for radiotherapy treatment planning for prostate cancer. It is designed to simplify workflow and eliminate cumbersome MR-CT registration.

arrow 3
pinnacle-thumbnail

 

Discover Pinnacle³ Auto-Planning

Creating IMRT and VMAT plans can be labor-intensive and time-consuming. Automation on Pinnacle³ Auto-Planning is designed to simplify and accelerate the complex planning process and put consistent results at your fingertips.

*MR-only simulation is not CE marked.

This material is not for distribution / use in the USA.

Interested in more information?

Fill out your contact details and our representative will be happy to assist you further.

*

Contact information

* This field is mandatory

*
*
*
*
*
*
*
*
*

By specifying your reason for contact we will be able to provide you with a better service.

We work with partners and distributors who may contact you about this Philips product on our behalf.

*
*

Final CEE consent

cross symposium

You are about to visit a Philips global content page

Continue

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.